Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR
Company Acquires Phase II-Ready Prothena Drug
The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.
You may also be interested in...
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.